Osteoporosis drugs' long-term use needs more research, FDA reports

May 13, 2014
Osteoporosis drugs' long-term use needs more research: FDA
Review of bisphosphonates finds they work but optimum time for use remains unclear.

(HealthDay)—The long-term risks and benefits of taking bisphosphonates, a class of drugs widely used for osteoporosis, require more research, according to the U.S. Food and Drug Administration.

Bisphosphonates have been used in the United States since 1995 to treat people with osteoporosis, a condition in which bones become weak and are at increased risk of breaking. More than 44 million Americans are at risk for osteoporosis.

"These drugs clearly work. We just don't know yet the optimum period of time individual patients should be on the to both maximize its effectiveness and minimize potential risks," Dr. Marcea Whitaker, the review's co-author and a medical officer at the FDA's Center for Drug Evaluation and Research, said in an agency news release.

The FDA review of clinical studies assessed the effectiveness of long-term bisphosphonate use and concluded that some patients can stop using the drugs after three to five years and still continue to get their benefit.

But the review, which was published in 2012 in the New England Journal of Medicine, also called for more research into the drugs, sold under the brand names of Actonel, Atelvia, Boniva and Fosamax, along with generics.

Specifically, investigators need to learn more about patients' fracture risk after they stop taking the drugs, and whether resuming them later could be helpful, Whitaker said.

The studies included in the review indicate that it may be prudent for patients with a low risk for fractures—younger patients who have near-normal bone density and no history of fractures, for example—to stop using bisphosphonates after three to five years.

However, continued use of bisphosphonates may benefit patients at increased risk for fractures, such as older patients with and a history of fractures.

There are a number of potential risks associated with bisphosphonates, including severe jaw bone decay and unusual thigh bone fractures. The FDA is currently examining a possible link between bisphosphonates and esophageal cancer.

Due to these , doctors may want to reconsider how long should take bisphosphonates, the FDA news release said.

If you're taking bisphosphonates, talk to your doctor about whether or not you should continue taking the drugs, and re-evaluate the decision periodically, Whitaker said. Do not stop taking these drugs without first talking to your doctor.

Tell your doctor if you develop any new hip or thigh pain, or have any concerns about taking bisphosphonates. Report unusual side effects of to the FDA's MedWatch program.

Explore further: Study provides guidance on drug holidays from popular osteoporosis treatments

More information: The National Osteoporosis Foundation has more about osteoporosis medicines.

Related Stories

Study provides guidance on drug holidays from popular osteoporosis treatments

January 15, 2014
Doctors commonly recommend drug holidays, or breaks, from certain osteoporosis drugs due to the risks associated with these treatments. Yet little has been known about the ideal duration of the holidays and how best to manage ...

Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half

February 8, 2012
There is growing evidence that supports an association between atypical fractures of the femur– a rare break of the thigh bone, typically without trauma – and the use of bisphosphonates, drugs proven to enhance ...

Bisphosphonates could offer effective pain relief in osteoarthritis, research finds

September 6, 2013
St George's, University of London research has found that a drug normally given to osteoporosis sufferers could provide effective pain relief to patients with knee and hip osteoarthritis.

Recommended for you

Flu may be spread just by breathing, new study shows; coughing and sneezing not required

January 18, 2018
It is easier to spread the influenza virus (flu) than previously thought, according to a new University of Maryland-led study released today. People commonly believe that they can catch the flu by exposure to droplets from ...

Zika virus damages placenta, which may explain malformed babies

January 18, 2018
Though the Zika virus is widely known for a recent outbreak that caused children to be born with microencephaly, or having a small head, and other malformations, scientists have struggled to explain how the virus affects ...

Study reveals how MRSA infection compromises lymphatic function

January 17, 2018
Infections of the skin or other soft tissues with the hard-to-treat MRSA (methicillin-resistant Staphylococcus aureus) bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. ...

New study validates clotting risk factors in chronic kidney disease

January 17, 2018
In late 2017, researchers from Boston University School of Medicine (BUSM) discovered and published (Science Translational Medicine, (9) 417, Nov 2017) a potential treatment target to prevent chronic kidney disease (CKD) ...

Fresh approach to tuberculosis vaccine offers better protection

January 17, 2018
A unique platform that resulted in a promising HIV vaccine has also led to a new, highly effective vaccine against tuberculosis that is moving toward testing in humans.

Newly-discovered TB blood signal provides early warning for at-risk patients

January 17, 2018
Tuberculosis can be detected in people with HIV infection via a unique blood signal before symptoms appear, according to a new study by researchers from the Crick, Imperial College London and the University of Cape Town.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.